仑伐替尼肝癌全病程应用中国专家指导意见  

Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma

作　　者：杨欣荣 孙惠川 谢青[2] 张万广[3] 荚卫东 赵明[5] 赵海涛[6] 刘秀峰 周乐杜[8] 严盛 徐立[10] 王楠娅[11] 丁元 朱小东 周俭 樊嘉 Yang Xinrong;Sun Huichuan;Xie Qing;Zhang Wanguang;Jia Weidong;Zhao Ming;Zhao Haitao;Liu Xiufeng;Zhou Ledu;Yan Sheng;Xu Li;Wang Nanya;Ding Yuan;Zhu Xiaodong;Zhou Jian;Fan Jia(Department of Liver Surgery,Research Institute of Liver Cancer,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Infectious Diseases,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Hepatic Surgery Center,Tongji Hospital,Tonji Medical College,Huazhong University of Science and Technolog,Wuhan 430030,China;Department of Liver Surgery,the First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,China;Department of Minimally Invasive and Interventional,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Guangzhou 510060,China;Department of Hepatic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Oncology,Qinhuai Medical District,Eastern Theater General Hospital of PLA,Nanjing 210002,China;Department of Liver Surgery,Xiangya Hospital of Central South University,Changsha 410008,China;Department of Hepatobiliary and Pancreatic Surgery,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Liver Surgery,Sun Yat‐sen University Cancer Center,Guangzhou 510060,China;Department of Cancer Center,the First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]复旦大学附属中山医院肝脏外科、肝癌研究所,上海200032 [2]上海交通大学医学院附属瑞金医院感染科,上海200025 [3]华中科技大学同济医学院附属同济医院肝脏外科中心,武汉430030 [4]中国科学技术大学附属第一医院肝脏外科,合肥230001 [5]中山大学肿瘤防治中心微创介入治疗科华南国家重点实验室,广州510060 [6]中国医学科学院北京协和医院肝脏外科,北京100730 [7]东部战区总医院秦淮医疗区肿瘤科,南京210002 [8]中南大学湘雅医院肝脏外科,长沙410008 [9]浙江大学医学院附属第二医院肝胆胰外科,杭州310009 [10]中山大学肿瘤防治中心肝脏外科,广州510060 [11]吉林大学第一医院肿瘤中心,长春130021

出　　处：《中华消化外科杂志》2023年第2期167-180,共14页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金(82072715);上海市卫健委协同创新集群计划(2019CXJQ02)。

摘　　要：甲磺酸仑伐替尼是一种针对血管内皮生长因子受体1~3、成纤维细胞生长因子受体1~4、血小板衍生生长因子受体α、干细胞生长因子受体以及转染重排基因等靶点的口服酪氨酸激酶受体抑制剂。该药于2018年9月4日经我国国家药品监督管理局批准,用于治疗未接受过系统治疗的不可切除肝细胞癌患者。截至2023年2月,仑伐替尼已在我国上市4年余,积累了一系列临床研究证据。为了临床上更加合理、有效使用仑伐替尼,国内相关领域的多学科专家学者,采用德尔菲法,根据仑伐替尼上市前后的临床实践,参考其他抗血管生成抑制剂的使用经验,经过多次共同讨论,反复修改,最终形成《仑伐替尼肝癌全病程应用中国专家指导意见》,以供临床医师参考。Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3,fibroblast growth factor receptors 1-4,platelet-derived growth factor receptorα,stem cell growth factor receptor,and rearranged during transfection,et al.Lenvatinib has been approved by the National Medical Products Administration of China on September 4,2018,for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before.Up to February 2023,Lenvatinib has been listed in China for more than 4 years,accumulating a series of post-marketing clinical research evidences.Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors,domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions,in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.

关 键 词：肝肿瘤 仑伐替尼 肝细胞癌 系统治疗 全程管理 合理应用 安全性 

分 类 号：R735.7[医药卫生—肿瘤]